Molecular understanding of combination epigenetic therapy in MLL-fusion leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1066545

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The poor prognosis conferred by chromosome breaks involving the MLL gene in acute leukaemia has not significantly changed in over twenty years. This fact highlights the urgent need to identify and develop novel therapeutic agents for this disease. This project will aim to understand the mechanisms leading to the initiation and maintenance of this aggressive disease. We will then use these insights to develop a rational combination of therapeutic agents.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $624,660.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematological Tumours

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer cell biology | chromatin | epigenetics | leukaemia | targeted therapy | transcriptional regulation

Related Links